What is CADL's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.76B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for CADL?

P/E (TTM) is n/a and 52-week range is $4.35 to $14.00 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s CADL figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for CADL?

The company profile lists revenue (TTM) near $124K, net income (TTM) near $-1.88B, EPS (TTM) near $-1.41 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Candel Therapeutics Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Needham, Massachusetts, US, 73.3M shares outstanding, ISIN US1374041093 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Candel Therapeutics Inc

$CADL

Health Care · Biotechnology

IR Run Scenarios

$9.94

+2.90%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Candel Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the development and commercialization of viral immunotherapies. The company is headquartered in Needham, Massachusetts and currently employs 55 full-time employees. The company went IPO on 2021-07-27. CAN-2409 is the lead product candidate from the adenovirus platform. CAN-3110 is the lead product candidate from the herpes simplex virus (HSV) platform and is in an ongoing phase Ib clinical trial in recurrent high-grade glioma. Its enLIGHTEN Discovery Platform is a systematic, iterative HSV-based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapies for solid tumors. CAN-2409, Its advanced multimodal biological immunotherapy candidate, is an investigational, off-the-shelf, replication-defective adenovirus engineered to deliver the herpes simplex virus thymidine kinase (HSV-tk) gene to a patient’s specific tumor and induce an individualized, systemic immune response against the tumor.

Employees

Website

www.candeltx.com/

IPO

2021-07-27

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)